Volume 8, Issue 2 (7-2010)                   IJRM 2010, 8(2): 86-89 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghasemi N, Mortazavizadeh M R, Khorasani Gerdekoohi A. Frequency of poly cystic ovary syndrome in patients with premenopausal breast cancer. IJRM 2010; 8 (2) :86-89
URL: http://ijrm.ir/article-1-173-en.html
Frequency of poly cystic ovary syndrome in patients with premenopausal breast cancer
Nasrin Ghasemi * 1, Mohammad Reza Mortazavizadeh2 , Aboolfazl Khorasani Gerdekoohi3
1- Department of Medical Genetics, Research and Clinical Centre for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Department of Oncology, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- Medical School, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract:   (3005 Views)
Background: Polycystic ovary syndrome (PCOS) is a heterogeneous complex genetic disorder characterized by hyperandrogenemia hyperinsulinemia insulin resistance and chronic anovulation. It is the most common endocrine disorder in women of reproductive age with an enigmatic pathophysiologic and molecular basis. Obesity hyperandrogenism and infertility occur frequently in PCOS which mostly have a genetic predisposition and are features known to be associated with the development of breast cancer risk.
Objective: In present study frequency of PCOS in patients with premenopausal breast cancer was compared with the frequency in women without breast cancer.
Materials and Methods: This is a case-control study which compared PCOS frequency in 166 patients with premenopausal breast cancer and 166 healthy controls with normal mammography in last 6 months.
Results: Eleven patients (6.62%) in case group and 16 patients (9.63%) in control group had polycystic ovary syndrome according to their questionnaire. The difference was not significant (p=0.645).
Conclusion: There was no relationship between frequency of polycystic ovary syndrome and breast cancer in this study. This might be due to the age of patients with breast cancer in this study which was mostly over 40. It could be significant if the patients were chosen in lower age for showing more effect of genetic than environment. The adjustment or matching of other risk factors could help to find the better results.
Keywords: Polycystic ovary syndrome, Premenopausal breast cancer, Endocrine disorder.
Full-Text [PDF 91 kb]   (588 Downloads) |   |   Full-Text (HTML)  (354 Views)  
Type of Study: Original Article |
References
1. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-312. [DOI:10.1210/er.2003-0004]
2. Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 2004; 191: 713- 717. [DOI:10.1016/j.ajog.2004.04.045]
3. Spritzer PM, Morsch DM, Wiltgen D. Polycystic ovary syndrome associated neoplasms. Arq Bras Endocrinol Metabol 2005; 49: 805-810. [DOI:10.1590/S0004-27302005000500022]
4. Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 1997; 79: 494-499. https://doi.org/10.1002/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.0.CO;2-Z [DOI:10.1002/(SICI)1097-0142(19970201)79:33.0.CO;2-Z]
5. Helewa M, Levesque P, Provencher D, Lea RH, Rosolowich V, Shapiro HM. Breast Disease Committee and Executive Committee and Council, Society of Obstetricians and Gynaecologists of Canada. Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can 2002; 24:164–180. [DOI:10.1016/S1701-2163(16)30298-5]
6. Ross RK. Breast cancer: epidemiology, pathology, and natural history. In: Genazzani AR, editor. Hormone replacement therapy and cancer. The current status of research and practice. New York: Parthenon Publishing; 2002; 31–37.
7. Secreto G, Zumoff B. Abnormal production of androgens in women with breast cancer. Anticancer Res 1994; 14: 2113–2117.
8. Kaaks R. Nutrition, hormones, and breast cancer: Is insulin the missing link? Cancer Causes Control 1996;7: 605–625 [DOI:10.1007/BF00051703]
9. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia 2009; 13:90-92.
10. Moini A, Eslami B. Familial associations between polycystic ovarian syndrome and common diseases. J Assist Reprod Genet 2009; 26: 123-127. [DOI:10.1007/s10815-009-9297-7]
11. Thiboutot DM, Harper JC, O'Connell K, Rich P, Sondheimer SJ. Improving outcomes through collaboration. Cutis 2008; 81 (Suppl. 1): 26-31
12. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009 ;19: 398-405. [DOI:10.1016/S1472-6483(10)60175-7]
13. Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991; 134: 818- 824. [DOI:10.1093/oxfordjournals.aje.a116156]
14. Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N, Luborsky JL. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 1990; 70: 421–430. [DOI:10.1210/jcem-70-2-421]
15. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001; 7: 522–525. [DOI:10.1093/humupd/7.6.522]
16. Atiomo WU, El-Mahdi E, Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertil Steril 2003; 80: 143–145. [DOI:10.1016/S0015-0282(03)00502-8]
17. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at longterm follow-up. J Clin Epidemiol 1998; 51: 581–586. [DOI:10.1016/S0895-4356(98)00035-3]
18. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil 2000; 3: 101–105. [DOI:10.1080/1464727002000198781]
19. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997; 6: 397–402. [DOI:10.1093/hmg/6.3.397]
20. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (tttta) (n) at 7528 base pairs of gene CYP11aa influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000; 73: 735–741. [DOI:10.1016/S0015-0282(99)00628-7]
21. Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update 2001; 7: 405– 410. [DOI:10.1093/humupd/7.4.405]
22. Daneshmand S, Weitsman SR, Navab A, Jakimiuk AJ, Magoffin DA. Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17ahydroxylase/ C (17-20) lyase promoters. Fertil Steril 2002; 77: 274–280. [DOI:10.1016/S0015-0282(01)02999-5]
23. Zheng W, Gao YT, Shu XO, Wen W, Cai Q, Dai Q, et al. Population-based case–control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 709–714.
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb